Rybelsus (Semaglutide) 14 mg, 10 tablets: profile, composition and research
Reference page for Rybelsus (Semaglutide) 14 mg, 10 tablets. Active substance: Семаглутид / Semaglutide.
- What it is: semaglutide, a GLP-1 receptor agonist supplied as tablets for oral use.
- Presentation: 14 mg tablets, 10 tablets per pack.
- Status: prescription-only medicine.
- Research: work on glycaemic control and on cardiovascular outcomes in type 2 diabetes, links below.
- Where to buy: APV Pharmacy (price and availability there).
Key facts
| Active substance | Semaglutide |
|---|---|
| Form | Tablets for oral use |
| Strength | 14 mg per tablet |
| Pack size | 10 tablets |
| Category | Prescription medicine |
| Article (SKU) | RYBELSUS-14-10 |
What oral semaglutide is
Semaglutide is a synthetic analogue of GLP-1 (glucagon-like peptide-1), a hormone the intestine releases after a meal. The molecule was modified so that it lasts in the body far longer than the natural hormone.
A tablet is an unusual form for this class. Most GLP-1 based medicines are given by subcutaneous injection, whereas here the active substance crosses the lining of the stomach. That route became possible through an auxiliary technology that helps a large molecule pass the absorption barrier.
Each pack holds 10 tablets of 14 mg. This is the highest strength in the oral semaglutide range. The presentation and pack size are listed above; choosing the strength is a physician's decision.
How semaglutide works
The pancreas
The substance binds to GLP-1 receptors and increases insulin release at the moment blood glucose is elevated. At the same time the output of glucagon, a hormone with the opposite effect, goes down.
Stomach and gut
Semaglutide slows gastric emptying, so food stays longer and the rise in sugar after a meal is smoother.
Appetite
GLP-1 takes part in the satiety centres of the brain, which is why the substance affects hunger and the size of a portion.
Glucose dependence
The boost to insulin release is tied to the current sugar level. That is what separates this mechanism from insulin and from sulfonylurea drugs.
Approved uses
The medicine is registered for adults who live with type 2 diabetes, to help keep blood glucose under control alongside diet and physical activity.
In type 1 diabetes and in diabetic ketoacidosis semaglutide is not used. It is not insulin, and it does not replace insulin where glucose has to come down quickly.
The oral form calls for strict adherence to the rules of use, so a physician explains them in detail at prescribing. A reference page does not replace that instruction.
What to keep in mind
The most frequent adverse events involve the digestive tract: nausea, vomiting, diarrhoea, constipation, abdominal pain and reduced appetite. They are usually more pronounced in the first weeks.
Serious risks include pancreatitis, gallbladder disease and dehydration from prolonged vomiting or diarrhoea. Severe and persistent abdominal pain calls for medical help.
Medullary thyroid carcinoma in the patient or in blood relatives, and also MEN 2 syndrome, rule the medicine out. Kidney disease, diabetic retinal damage, pregnancy or plans for it, and every other medicine taken should be reported to a doctor.
Published research
Primary sources, verified against PubMed:
- Oral Semaglutide and CV Benefits in the SOUL Trial: How Do Baseline or Changes in HbA1c or BMI Affect Clinical Outcomes?, PubMed 42478869 (J Clin Endocrinol Metab, 2026).
- Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis., PubMed 42567173 (Lancet Diabetes Endocrinol, 2026).
- The expanding role of semaglutide: beyond glycemic control., PubMed 40620322 (J Diabetes Metab Disord, 2025).
Listed for reference. Publication of a study is not a claim about this particular product.
Precautions
- This is a prescription medicine. Prescribing, choice of strength and monitoring belong to a physician.
- The oral form is sensitive to the rules of use, which a physician explains in detail. The tablet is swallowed whole, not crushed or chewed.
- Medullary thyroid carcinoma in the patient or in relatives, as well as MEN 2 syndrome, excludes the use of semaglutide.
- Nausea, vomiting, diarrhoea, constipation and abdominal pain are possible. Severe and persistent abdominal pain requires urgent medical help.
- Combined with insulin or a sulfonylurea the risk of hypoglycaemia rises; the regimen is adjusted by a physician.
- Pregnancy and breastfeeding are discussed with a doctor individually. A planned pregnancy should be reported in advance.
- Tell your doctor about kidney or liver disease and about every other medicine you take.
Frequently asked
Is Rybelsus a prescription medicine?
Yes. It is a prescription medicine and is not intended for self-medication.
Why does this page not give a dosing schedule?
The rules of use for the oral form matter a great deal, and a physician sets them according to the patient's condition. This reference page does not prescribe treatment.
Can it be used in type 1 diabetes?
No. It is registered for type 2 diabetes and does not replace insulin.
Where does the order ship from?
Shipping and customs handling are described on the APV Pharmacy delivery page.